Elsiglutide

also known as: ZP1846

Zealand's early GLP-2 analog program (Phase 2 for chemotherapy-induced diarrhea) — superseded by glepaglutide in Zealand's GLP-2 pipeline; retained for pipeline-history completeness.

An early GLP-2 analog (Zealand Pharma, ZP1846) investigated in Phase 2 for chemotherapy-induced diarrhea; subsequently superseded within Zealand's pipeline by glepaglutide, which advanced to Phase 3 SBS.

Mechanism of action

GLP-2 receptor agonism — same intestinotrophic mechanism class as teduglutide.

Primary uses

Historical: chemotherapy-induced diarrhea (Phase 2)

Typical dosing

(subcutaneous)

Program-level data only.

Regulatory status

Not approved. Phase 2 program for chemotherapy-induced diarrhea; superseded by glepaglutide in Zealand Pharma's GLP-2 pipeline.

References

[manufacturer] Zealand Pharma pipeline disclosures (historical GLP-2 program ZP1846).

Related peptides

Teduglutide

FDA-approved GLP-2 analog (Gattex/Revestive, 2012) for short-bowel syndrome — the first disease-modifying treatment for SBS, reducing parenteral nutrition dependence by promoting intestinal mucosal growth.

Glepaglutide

Zealand Pharma's long-acting GLP-2 analog for short-bowel syndrome — Phase 3 EASE program completed 2023 with mixed results (primary endpoint not met in EASE-1 under the prespecified analysis, though post-hoc and secondary analyses were positive); regulatory path under review.

Disclaimer

This entry is for educational purposes only and does not constitute medical advice. Dosing information reflects published regulatory or research data and is not a recommendation. Many compounds described here are not approved for human use in the United States. Consult a licensed medical professional before considering any peptide therapy.